Science

Occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease

Eva Kempers/LinkedIn

Jan 29, 2025, 21:39

Occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease

Sebastian Szmit, Consultant at the Maria Sklodowska-Curie National Research Institute of Oncology, shared an article by Eva Kempers et al. on LinkedIn:

“Next great study published by the research group associated with the SERENITY trial supported by European Commission.

I am proud to be part of this scientific adventure!”

Discontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease.

Authors: Eva Kempers, et al.

Occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease

cancer European Commission Eva Kempers fight against cancer Global fight against cancer Maria Sklodowska-Curie National Research Institute of Oncology OncoDaily Oncology Sebastian Szmit SERENITY trial

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute